Immune Checkpoint Inhibitor–Associated Uveitis Treated with the 0.19 Mg Fluocinolone Acetonide Intravitreal Implant: Clinical Outcomes in a Retrospective Case-Series

PURPOSE: To evaluate the effectiveness and safety of the 0.19 mg fluocinolone acetonide (FAc) intravitreal implant for the management of immune checkpoint inhibitor (ICI)-associated uveitis. METHODS: Multicenter retrospective case-series including patients who developed uveitis during ICI therapy and were treated with a 0.19 mg FAc implant. The primary outcome was complete resolution of intraocular inflammation at the last follow-up visit (LFUV). Secondary outcomes included changes in best-reported visual acuity (BRVA), central retinal thickness (CRT), anterior chamber cell (ACC) and flare grades, vitreous haze (VH), intraocular pressure (IOP), need for adjunctive anti-inflammatory therapy, and modifications in ICI treatment. RESULTS: < 0.001 for all comparisons). IOP remained stable, with one transient elevation successfully controlled with topical therapy. Requirement for adjunctive anti-inflammatory treatment declined progressively after implantation. Most patients were able to continue or resume ICI therapy during follow-up. CONCLUSIONS: The 0.19 mg FAc intravitreal implant provided sustained control of inflammation, significant visual improvement, and reduced treatment burden in patients with ICI-associated uveitis. This local therapeutic approach may facilitate continuation of systemic immunotherapy while maintaining ocular disease control.